Please ensure Javascript is enabled for purposes of website accessibility

This Megadeal Caused Nektar Therapeutics' 11% Spike Today

By Todd Campbell - Updated Feb 14, 2018 at 5:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A big-cap biotech is cozying up with the company on one of its most important drugs.

What happened

After Bristol-Myers Squibb (BMY 0.56%) inked a multibillion-dollar deal for licensing rights to NKTR-214, Nektar Therapeutics' (NKTR -5.04%) shares rallied 11.02% on Wednesday.

So what

Nektar Therapeutics' promising pipeline of drugs helped turn its shares into one of 2017's top-performing stocks and the momentum continued today following news that big-cap biopharma Bristol-Myers has agreed to pay big money for 35% of the potential profit associated with NKTR-214.

A person points at a tablet displaying stock quotes and an ascending bar chart.


Specifically, Bristol-Myers Squibb is paying Nektar Therapeutics $1.85 billion up front, comprising $1 billion in cash and an equity investment of $850 million. The former has also agreed to pay the latter an additional $1.78 billion in milestones, of which $1.43 billion is tied to development and regulatory milestones, with the remainder payable if NKTR-214 achieves specific sales milestones. 

In return, Bristol-Myers Squibb gets nearly 8.3 million shares of Nektar Therapeutics at a price of $102.60 per share, and if NKTR-214's trials succeed, it can receive 35% of its global profit. Nektar Therapeutics retains the right to evaluate NKTR-214 in combination with other cancer drugs, so long as those relationships don't target the same mechanism of action as studies being conducted with Bristol-Myers Squibb. 

Bristol-Myers Squibb will pick up a substantial amount of the tab associated with combination studies that involve NKTR-214's use alongside its Opdivo and Yervoy. It will also cover 67.5% of development costs for studies involving only NKTR-214 and Opdivo, and will pay 78% of the costs having to do with triplet studies that include NKTR-214, Opdivo, and Yervoy.

Now what

Rumors have been swirling that a deal could be in the works for Nektar Therapeutics lock, stock, and barrel and this licensing agreement provides compelling conviction that Nektar Therapeutics is on to something big with NKTR-214, a solid-tumor cancer drug that activates T cells and natural killer cells directly in tumors and increases PD-L1 expression so that immuno-oncology drugs like Opdivo work better.

Bristol-Myers Squibb's deal suggests that it thinks data from ongoing NKTR-214 will be good. Prior results include a 91% disease control rate in 11 treatment-naive stage IV melanoma patients, a 79% disease control rate in 13 first-line stage 4 kidney cancer patients, and 75% disease control rate in four stage 4 non-small cell lung cancer patients. Additional data from trials, including a previously ongoing combination of NKTR-214 plus Opdivo, are expected soon. 

Nektar Therapeutics also has another important catalyst fast approaching. It plans to file NKTR-181 for Food and Drug Administration approval in chronic back pain during Q2 2018. NKTR-181 is intriguing because it's a slow-release medicine that results in less euphoria than existing opioid pain treatments.

Overall, I think this deal is a win because Nektar Therapeutics lands a deep-pocketed partner with extensive experience in NKTR-214's target indications while also retaining significant optionality on this drug. Furthermore, it gives Nektar Therapeutics the option still to find a collaboration partner on NKTR-181 and other cancer-fighting drugs further back in its pipeline. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nektar Therapeutics Stock Quote
Nektar Therapeutics
$3.39 (-5.04%) $0.18
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$77.13 (0.56%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.